Episode 23 - Greg Kunst and Corneal Endothelial Therapy for Partial or Full Vision Loss

The Future of Pharma

My guest in this episode is Greg Kunst, CEO of Aurion Biotech.

At Aurion, Greg and his colleagues are working on a regenerative treatment (corneal endothelial cell therapy) for millions of people who have partial or complete vision loss.

Greg joined Aurion Biotech with deep and varied experience in ophthalmic medical devices, drug delivery systems, diagnostics, biotechnology, and pharmaceutical products. His expertise spans global corporate development, strategy, health policy, marketing, commercialization, business development, market access and medical affairs.

Before Aurion Biotech, Greg spent 6 years at Glaukos Corporation (NYSE: GKOS) in numerous roles of increasing responsibility, most recently as vice president of global marketing.

Before Glaukos, Greg worked at Alcon, a Novartis company, as global franchise director over the Alcon glaucoma surgery and retina pharmaceutical businesses.

Greg is a board member of Pr3vent. He received an MBA from Vanderbilt University and a BS in Economics from Brigham Young University.

In this interview, Greg talks about why he decided to dedicate his life to eye therapies, the origin of Aurion (Dr. Shigeru Kinoshita's research in Corneal Endothelial Cell Therapy), how he remains positive in spite of being a self-proclaimed news junkie, and his unequivocal commitment to making Aurion therapies affordable for everyone.

I thoroughly enjoyed my chat with Greg. Hope you do too.